Dual inhibition of HSP27 and FAO with ivermectin and perhexiline enhances the cytotoxic effect of cisplatin, serving as a promising therapeutic strategy for cisplatin-resistant ovarian cancer. The gene discussed is HSPB1; the disease is ovarian carcinoma.